Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Halliwell B, Gutteridge JMC
Proper handling, storage, and disposal practices must be followed
In January 2026, the company announced a strategic initiative to expand its PharmaPatch microneedle patch platform into select therapeutic peptides
Rybelsusoral tablets are specifically FDA-labeled to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events
A randomized, placebo-controlled Phase 2 trial (NCT02453711) of once-daily subcutaneous semaglutide (0.05, 0.1, 0.2, 0.3, or 0.4 mg following 4-weekly escalations) in subjects with obesity without T2D, showed mean weight losses of -6.0% (0.05 mg) to -13.8% (0.4 mg) with semaglutide vs -2.3% with placebo at week 52
